HuMAB companies Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : HuMAB companies

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: scaram(o)uche who wrote (416)	10/2/2002 11:09:44 AM
From: nigel bates	Read Replies (2) of 1022

why aren't more antibodies described, from academic collaborators, in the literature? XenoMouse or HuMab, a search comes up with few recent successes. And those involve bacteria, bacterial toxins, and HIV... I don't have an answer to the question - not that it doesn't worry me... I do have a lot more CAT than ABGX. As regards getting MABs into the clinic, is it possible that the current environment is making companies overcautious about committing to trials ? Interesting snippet from today's CRGN PR, though - "...101 antibody projects, from which 28 fully human monoclonal antibodies are being evaluated in conjunction with Abgenix as potential therapeutics..." Back in May - "...The development of PDGF D mAbs is an important example of one of the 17 mAbs we are currently evaluating with Abgenix..."

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next